Needham Reiterates Buy on Intra-Cellular Therapies, Maintains $100 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a Buy rating on Intra-Cellular Therapies (NASDAQ:ITCI) and maintained a $100 price target.
August 08, 2024 | 11:35 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia has reiterated a Buy rating on Intra-Cellular Therapies (NASDAQ:ITCI) and maintained a $100 price target.
The reiteration of a Buy rating and the maintenance of a $100 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100